Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naronapride - Renexxion

Drug Profile

Naronapride - Renexxion

Alternative Names: ATI-7505

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Dr Falk Pharma; Renexxion
  • Class Anti-inflammatories; Benzamides; Gastrokinetics; Laxatives; Quinuclidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation; Gastro-oesophageal reflux; Gastroparesis; Non-ulcer dyspepsia
  • Discontinued Erosive oesophagitis

Most Recent Events

  • 07 Feb 2024 Renexxion expands its licensing and collaboration agreement with Dr. Falk Pharma to develop and commercialise Naronapride for Gastro-oesophageal reflux in Greater Europe (including UK), Russia, Central Asian Republics, and certain Australasian countries
  • 24 Jan 2024 Renexxion Ireland plans a phase IIb trial for Gastroesophageal reflux disease in USA in 2024
  • 24 Jan 2024 Renexxion Ireland files an IND application with the US FDA in USA for Gastro-oesophageal reflux, prior to January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top